



Toxicological Profile for Tetrachloroethylene

June 2019



U.S. Department of Health and Human Services
Agency for Toxic Substances and Disease Registry

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

UPDATE STATEMENT

A Toxicological Profile for Tetrachloroethylene, Draft for Public Comment was released in October 2014. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences
Environmental Toxicology Branch
1600 Clifton Road NE
Mailstop S102-1
Atlanta, Georgia 30329-4027

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the most informative (i.e., key) literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

- (A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Patrick N. Breyse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

QUICK REFERENCE FOR HEALTH CARE PROVIDERS

Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances may find the following information helpful for fast answers to often-asked questions.

Primary Chapters/Sections of Interest

Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance's relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure.

Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, and assesses the significance of toxicity data to human health.

Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type of health effect (e.g., death, systemic, immunologic, reproductive), by route of exposure, and by length of exposure (acute, intermediate, and chronic). In addition, both human and animal studies are reported in this section. Note that for epidemiological studies, there could be multiple routes of exposure.

NOTE: Not all health effects reported in this section are necessarily observed in the clinical setting. Please refer to the Public Health Statement to identify general health effects observed following exposure.

Pediatrics: Four new sections have been added to each Toxicological Profile to address child health issues:

Chapter 1	How Can (Chemical X) Affect Children?
Chapter 1	How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7	Children's Susceptibility
Section 6.6	Exposures of Children

Other Sections of Interest:

Section 3.8	Biomarkers of Exposure and Effect
Section 3.11	Methods for Reducing Toxic Effects

ATSDR Information Center

Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)

Internet: <http://www.atsdr.cdc.gov>

The following additional materials are available online:

Case Studies in Environmental Medicine are self-instructional publications designed to increase primary health care providers' knowledge of a hazardous substance in the environment and to aid in the evaluation of potentially exposed patients (see <https://www.atsdr.cdc.gov/csem/csem.html>).

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident (see <https://www.atsdr.cdc.gov/MHMI/index.asp>). Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances (see <https://www.atsdr.cdc.gov/toxfaqs/Index.asp>).

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015 • Web Page: <https://www.cdc.gov/nceh/>.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 395 E Street, S.W., Suite 9200, Patriots Plaza Building, Washington, DC 20201 • Phone: 202-245-0625 or 1-800-CDC-INFO (800-232-4636) • Web Page: <https://www.cdc.gov/niosh/>.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212 • Web Page: <https://www.niehs.nih.gov/>.

The National Cancer Institute (NCI) is the federal government's principal agency for cancer research and training. Contact: NCI, BG 9609 MSC 9760, 9609 Medical Center Drive, Bethesda, MD 20892-9760 • Phone: 1-800-4-CANCER (1-800-422-6237).

Clinical Resources (Publicly Available Information)

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk

Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266 • Web Page:
<http://www.acoem.org/>.

The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with recognized expertise in medical toxicology. Contact: ACMT, 10645 North Tatum Boulevard, Suite 200-111, Phoenix AZ 85028 • Phone: 844-226-8333 • FAX: 844-226-8333 • Web Page:
<http://www.acmt.net>.

The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists who respond to questions from public health professionals, clinicians, policy makers, and the public about the impact of environmental factors on the health of children and reproductive-aged adults. Contact information for regional centers can be found at <http://pehsu.net/findhelp.html>.

The American Association of Poison Control Centers (AAPCC) provide support on the prevention and treatment of poison exposures. Contact: AAPCC, 515 King Street, Suite 510, Alexandria VA 22314 • Phone: 701-894-1858 • Poison Help Line: 1-800-222-1222 • Web Page:
<http://www.aapcc.org/>.

This page is intentionally blank.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Rae T. Benedict, Ph.D.
Nickolette Roney, M.S.
Obaid Faroon, Ph.D.
CDR Robert L. Williams, Ph.D.
Annette Ashizawa, Ph.D.
ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA

Heather Carlson-Lynch, S.M.
Julie Klotzbach, Ph.D.
Kim Zaccaria, Ph.D.
Kelly Salinas, Ph.D.
H. Danielle Johnson, B.S.
Mario Citra, Ph.D.
SRC, Inc., North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Environmental Toxicology Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled for tetrachloroethylene. The panel are experts who have knowledge of tetrachloroethylene's physical and chemical properties, toxicokinetics, key health endpoints, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended. The panel consisted of the following members:

1. Rodney R. Dietert, Ph.D., Professor of Immunotoxicology, College of Veterinary Medicine, Cornell University, Ithaca, New York;
2. Kelly G. Pennell, Ph.D., Civil and Environmental Engineering Department, University of Massachusetts-Dartmouth, North Dartmouth, Massachusetts; and
3. Jill E. Johnston, Ph.D., Department of Environmental Sciences & Engineering, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, North Carolina.

In addition to the above peer reviewers, the following reviewers provided comments on the carcinogenicity discussions in the profile.

1. Neela Guha, Scientist, Ph.D., M.P.H., IARC Monographs Programme, International Agency for Research on Cancer, World Health Organization, Lyon, France
2. Aaron Blair, Ph.D., National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, Maryland
3. Kate Z. Guyton, Ph.D., D.A.B.T., Scientist, IARC Monographs Programme, International Agency for Research on Cancer, World Health Organization, Lyon, France

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments and ATSDR's responses to the comments, exists as part of the administrative record for this compound. The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	i
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	vii
CONTRIBUTORS	xi
PEER REVIEW	xiii
CONTENTS.....	xv
LIST OF FIGURES	xix
LIST OF TABLES	xxi
1. PUBLIC HEALTH STATEMENT FOR TETRACHLOROETHYLENE.....	1
2. RELEVANCE TO PUBLIC HEALTH	9
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO TETRACHLOROETHYLENE IN THE UNITED STATES	9
2.2 SUMMARY OF HEALTH EFFECTS.....	10
2.3 MINIMAL RISK LEVELS (MRLs)	14
3. HEALTH EFFECTS	23
3.1 INTRODUCTION.....	23
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	23
3.2.1 Inhalation Exposure	24
3.2.1.1 Death.....	24
3.2.1.2 Systemic Effects.....	26
3.2.1.3 Immunological and Lymphoreticular Effects	71
3.2.1.4 Neurological Effects	73
3.2.1.5 Reproductive Effects.....	85
3.2.1.6 Developmental Effects.....	89
3.2.1.7 Cancer	92
3.2.2 Oral Exposure.....	119
3.2.2.1 Death.....	119
3.2.2.2 Systemic Effects.....	120
3.2.2.3 Immunological and Lymphoreticular Effects	144
3.2.2.4 Neurological Effects	146
3.2.2.5 Reproductive Effects.....	151
3.2.2.6 Developmental Effects.....	153
3.2.2.7 Cancer	156
3.2.3 Dermal Exposure.....	169
3.2.3.1 Death.....	169
3.2.3.2 Systemic Effects.....	170
3.2.3.3 Immunological and Lymphoreticular Effects	171
3.2.3.4 Neurological Effects	171
3.2.3.5 Reproductive Effects.....	171
3.2.3.6 Developmental Effects.....	172
3.2.3.7 Cancer	172
3.2.4 Other Routes of Exposure	172
3.2.4.1 Immunological and Lymphoreticular Effects	172
3.3 GENOTOXICITY	172
3.4 TOXICOKINETICS.....	178

3.4.1	Absorption.....	179
3.4.1.1	Inhalation Exposure	179
3.4.1.2	Oral Exposure	184
3.4.1.3	Dermal Exposure	184
3.4.2	Distribution	186
3.4.2.1	Inhalation Exposure	187
3.4.2.2	Oral Exposure	188
3.4.2.3	Dermal Exposure	189
3.4.3	Metabolism.....	189
3.4.3.1	Inhalation Exposure	193
3.4.3.2	Oral Exposure	195
3.4.3.3	Dermal Exposure	195
3.4.4	Elimination and Excretion.....	195
3.4.4.1	Inhalation Exposure	195
3.4.4.2	Oral Exposure	198
3.4.4.3	Dermal Exposure	199
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	200
3.5	MECHANISMS OF ACTION	209
3.5.1	Pharmacokinetic Mechanisms.....	209
3.5.2	Mechanisms of Toxicity.....	210
3.5.3	Animal-to-Human Extrapolations	215
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	216
3.7	CHILDREN'S SUSCEPTIBILITY	217
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	220
3.8.1	Biomarkers Used to Identify or Quantify Exposure to Tetrachloroethylene	221
3.8.2	Biomarkers Used to Characterize Effects Caused by Tetrachloroethylene.....	223
3.9	INTERACTIONS WITH OTHER CHEMICALS	224
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	226
3.11	METHODS FOR REDUCING TOXIC EFFECTS.....	228
3.11.1	Reducing Peak Absorption Following Exposure.....	229
3.11.2	Reducing Body Burden	229
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	230
3.12	ADEQUACY OF THE DATABASE	230
3.12.1	Existing Information on Health Effects of Tetrachloroethylene	230
3.12.2	Identification of Data Needs.....	232
3.12.3	Ongoing Studies	251
4.	CHEMICAL AND PHYSICAL INFORMATION.....	253
4.1	CHEMICAL IDENTITY.....	253
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	253
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	257
5.1	PRODUCTION	257
5.2	IMPORT/EXPORT	258
5.3	USE	261
5.4	DISPOSAL.....	261
6.	POTENTIAL FOR HUMAN EXPOSURE	263
6.1	OVERVIEW.....	263
6.2	RELEASES TO THE ENVIRONMENT	265
6.2.1	Air	266

6.2.2	Water.....	272
6.2.3	Soil.....	273
6.3	ENVIRONMENTAL FATE.....	273
6.3.1	Transport and Partitioning.....	273
6.3.2	Transformation and Degradation.....	278
6.3.2.1	Air.....	278
6.3.2.2	Water.....	279
6.3.2.3	Sediment and Soil.....	281
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT.....	282
6.4.1	Air.....	282
6.4.2	Water.....	287
6.4.3	Sediment and Soil.....	289
6.4.4	Other Environmental Media.....	289
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE.....	290
6.6	EXPOSURES OF CHILDREN.....	296
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES.....	297
6.8	ADEQUACY OF THE DATABASE.....	299
6.8.1	Identification of Data Needs.....	300
6.8.2	Ongoing Studies.....	303
7.	ANALYTICAL METHODS.....	305
7.1	BIOLOGICAL MATERIALS.....	305
7.2	ENVIRONMENTAL SAMPLES.....	309
7.3	ADEQUACY OF THE DATABASE.....	314
7.3.1	Identification of Data Needs.....	315
7.3.2	Ongoing Studies.....	316
8.	REGULATIONS, ADVISORIES, AND GUIDELINES.....	317
9.	REFERENCES.....	323
10.	GLOSSARY.....	377
APPENDICES		
A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS.....	A-1
B.	USER'S GUIDE.....	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	C-1

This page is intentionally blank.

LIST OF FIGURES

3-1. Levels of Significant Exposure to Tetrachloroethylene – Inhalation	50
3-2. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Bladder Cancer	102
3-3. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Non-Hodgkin's Lymphoma	103
3-4. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Multiple Myeloma	104
3-5. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Kidney Cancer	105
3-6. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Leukemia-Lymphoma.....	106
3-7. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Liver Cancer	107
3-8. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Pancreatic Cancer	108
3-9. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Prostate Cancer	109
3-10. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Breast Cancer.....	110
3-11. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Cervical Cancer	111
3-12. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Esophageal Cancer.....	112
3-13. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Rectal Cancer.....	113
3-14. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Lung Cancer	114
3-15. Summary of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Brain Cancer	115
3-16. Levels of Significant Exposure to Tetrachloroethylene – Oral	132
3-17. Summary of Epidemiological Studies Evaluating Associations between Oral Tetrachloroethylene and Breast Cancer.....	164

3-18. Summary of Epidemiological Studies Evaluating Associations between Oral Tetrachloroethylene and Hematopoietic Cancers.....	165
3-19. Summary of Epidemiological Studies Evaluating Associations between Oral Tetrachloroethylene and Other Cancers	166
3-20. Proposed Pathways for the Metabolism of Tetrachloroethylene	190
3-21. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	202
3-22. Overall Structure of PBPK Model for Tetrachloroethylene and Metabolites.....	204
3-23. Existing Information on Health Effects of Tetrachloroethylene.....	231
6-1. Frequency of NPL Sites with Tetrachloroethylene Contamination.....	264

LIST OF TABLES

3-1. Levels of Significant Exposure to Tetrachloroethylene – Inhalation	27
3-2. Overview of Epidemiological Studies Evaluating Associations between Inhaled Tetrachloroethylene and Cancer	93
3-3. Hepatocellular Neoplasms in Mice Exposed to Tetrachloroethylene for 103 Weeks by Inhalation.....	117
3-4. Levels of Significant Exposure to Tetrachloroethylene – Oral	121
3-5. Overview of Epidemiological Studies Evaluating Associations between Oral Tetrachloroethylene and Cancer	157
3-6. Genotoxicity of Tetrachloroethylene <i>In Vitro</i>	173
3-7. Genotoxicity of Tetrachloroethylene <i>In Vivo</i>	174
3-8. Partition Coefficients for Tetrachloroethylene in Mice, Rats, Dogs, and Humans	180
3-9. Metabolism of Tetrachloroethylene in Mice, Rats, and Humans	194
3-10. Baseline and Posterior Values of PBPK Model Parameters Selected for Optimization using MCMC.....	205
3-11. Ongoing Studies on Tetrachloroethylene	252
4-1. Chemical Identity of Tetrachloroethylene	254
4-2. Physical and Chemical Properties of Tetrachloroethylene	255
5-1. Facilities that Produce, Process, or Use Tetrachloroethylene.....	259
6-1. Releases to the Environment from Facilities that Produce, Process, or Use Tetrachloroethylene ...	267
6-2. Emissions of Tetrachloroethylene	269
6-3. Tetrachloroethylene Concentrations in Ambient Air for 2006.....	284
6-4. Percentile Distribution of Annual Mean Tetrachloroethylene Concentrations (ppb) Measured in Ambient Air at Locations Across the United States	285
6-5. Geometric Mean and Selected Percentiles of Tetrachloroethylene Blood Concentrations (in ng/mL) for the U.S. Population from NHANES	292
6-6. Ongoing Studies on Tetrachloroethylene	304
7-1. Analytical Methods for Determining Tetrachloroethylene in Biological Materials	307

7-2. Analytical Methods for Determining Tetrachloroethylene in Environmental Samples	310
8-1. Regulations, Advisories, and Guidelines Applicable to Tetrachloroethylene	319